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. Of note, no single model of genetic service delivery currently exists, and there is extensive variation within and across countries 2 . Advances in next-generation sequencing technologies have yielded genome-wide diagnostic tests (hereafter called genomic tests), which are based on multigene panels, whole-exome sequencing or whole-genome sequencing. Informed by both public and privately funded research, genomic tests are emerging in countries with advanced market economies 3 , such as the USA 4, 5 , Canada 6, 7 , France 8 and the UK 9 , and some genomic tests are starting to replace existing diagnostic strategies (including in some instances genetic tests) in clinical practice 10, 11 (TABLE 1).
Practising clinical geneticists understand the impact of the diagnostic odyssey on and cost-benefit analysis (CBA), are available to obtain this evidence. In some countries, such as Australia and the UK, national decision-making bodies use evidence of cost-effectiveness to inform clinical guidelines or reimbursement decisions. However, in contrast to most health-care interventions, the nature of the decision-maker charged with allocating finite health-care resources to genetic and genomic technologies, and associated diagnostic tests, is not well defined. Such decision-makers operate within different levels of existing health-care systems, and their roles and responsibilities differ within and across countries.
This Perspective reviews the role of CEA in informing the introduction of genetic and genomic tests for the diagnosis of inherited rare diseases or targeted therapies, with an emphasis on evaluative frameworks employed by national decision-making bodies, such as the National Institute for Health and Care Excellence (NICE) under the remit of the National Health Service (NHS) England. We review the key elements to consider in the CEA of genetic and genomic tests and services before specifically describing the potential of decision analytic model-based CEA as well as its methodological, technical, practical and organizational challenges. The emerging economic evidence base for genetic tests, but lack of associated evidence for genomic tests, is also summarized.
The cost of sequencing
The increase in the clinical application of genomic tests is generally credited to the decline in the cost of sequencing, which was facilitated by the move from Sanger sequencing to next-generation sequencing technologies. According to data from the National Human Genome Research Institute (NHGRI), until the end of 2007, the cost of sequencing a whole genome was estimated to be around US$10 million, which by late 2015 had fallen below $1,500 (REF. 14) . Large public and private funding programmes have the potential to drive down costs further by sequencing genomes at high volume and generating substantial economies of scale 15 . Consequently, the sequencing cost of whole-genome patients and their families. Published evidence also highlights the detrimental effect of the lack of a clear diagnosis of a condition that causes distressing symptoms 12 . Genomic tests may offer an increased chance of diagnosis by moving the gene-based diagnostic component to the front of the diagnostic care pathway 13 . Moreover, in some instances, genomic tests have the potential to inform treatment decisions. However, the existence of fixed annual health-care budgets alongside the continued development and emergence of new interventions to prevent or treat health conditions provides decision-makers charged with the allocation of health-care resources with an enduring challenge.
Evidence of the relative cost-effectiveness, which explicitly quantifies the additional resource use (costs) and consequences (benefits and harms) of a new intervention compared with other potential uses of a health-care budget, can provide decision-makers with useful information to guide decisions about resource allocation (FIG. 1) . Methods of economic evaluation, such as cost-effectiveness analysis (CEA) sequencing is on a trajectory to break the $1,000 barrier in the very near future 16 . However, most cost estimates within the literature (including those produced by the NHGRI for whole-genome sequencing) tend to focus largely on the procurement and resources used to run platforms but do not factor in the downstream analysis and interpretation of data that would be needed for use in routine clinical practice [17] [18] [19] . Hence, the currently available cost estimates of whole-genome sequencing are of limited use to decision-makers (FIG. 1) , who require a broader understanding of the costs of introducing genomic technologies into clinical practice.
Importantly, the cost of a technology differs from the price advertised to payers in a commercial setting. Prices of molecular scientist or bioinformatician); resources needed for data analysis and interpretation; and the capacity to deliver a sufficient number of tests.
Budget impact of genomic tests
The budget impact of introducing genomic tests into a health-care system, in terms of knowing the direct health-care resources required to implement widespread testing and then potentially changing treatment, is harder to quantify than the cost of performing sequencing, and to date no accurate published figures exist for the total budget impact of introducing genetic or genomic tests into practice. Budget impact estimates are a function of the expected current and future eligible population size, which is measured using are likely to be marked up for profit or to be cross-subsidized with other tests on offer. Websites such as Genohub (https://genohub.com/) provide a useful source of prices from a global network of laboratories offering next-generation sequencing-based tests, including whole-genome sequencing (price range $1,105-$16,420; prices as of October 2017), whole-exome sequencing (price range $534-$7,637) and gene panels (price range $400-$5,800). The cost of a complete sequencing service includes DNA preparation and is dependent on the number of samples required; sequencing coverage and depth; the number of reads; the platform used; general laboratory costs, such as overheads and skill mix (for example, salary costs for the relevant grade There is no accepted definition of how a genetic test differs from a genomic test. For the purpose of this paper, we use the following definitions: genetic tests aim to identify germline or somatic mutations (or pathogenic variants) that underlie high-risk, single-gene disorders, whereas genomic tests search for germline or somatic mutations (or pathogenic or modifying variants) in coding and non-coding DNA across the whole genome. Genomic tests are often applied to heterogeneous conditions, polygenic conditions or conditions with unknown genetic causes, including conditions where epigenetic factors may play a role in disease risk. CFTR, cystic fibrosis transmembrane conductance regulator; EGFR, epidermal growth factor receptor; HLA, human leukocyte antigen; NSCLC, non-small-cell lung cancer.
expected prevalence or incidence rates of the condition of interest multiplied by the acquisition cost (if tests are offered at cost) or the price of the technology used to diagnose and/or treat 20 . However, population size will change with a test that improves diagnostic yield, and tests may reveal incidental findings that can stimulate additional health-care costs 19 . Moreover, it is important to distinguish between the genomic technology used to perform the sequencing (such as a gene panel or whole-exome sequencing), the suitability and use of the technology as a diagnostic (that is, its capacity to provide an actionable test result) and the mechanism used to offer the relevant patient population the diagnostic service (model of service delivery) 21 . Even at a seemingly simplistic level, the actual cost of providing services to deliver genomic tests is not well documented. For example, in England, the cost of providing genomic medicine is embedded within specialist commissioned services 22 . However, evidence is starting to emerge for some example tests. The budget impact of introducing whole-exome sequencing to the front of the diagnostic pathway for patients with a high probability of having a rare inherited disease who attend special genetic services in the UK was estimated to lead to an increased pathway cost of £939 per patient (or a 52.5% increase) compared with the usual testing strategy 23 . Even if the population size is known with certainty, a fundamental challenge for estimating the budget impact of genetic and genomic tests is the lack of a transparent national tariff in some countries and the use of charges, such as a flat rate per gene, rather than the cost of delivering testing in terms of use of health-care resources in others 24 .
Opportunity cost
Allocating resources for one intervention for a specified population means that those same resources can no longer be used elsewhere for the care of other (known or unknown) patient populations. Economic evaluation provides an explicit framework to estimate the opportunity cost of introducing a new intervention by comparing relevant alternative uses of the health-care budget in terms of their costs and consequences 25 . Existing evaluation frameworks for genetic tests for rare inherited disorders 26, 27 are not consistent with methods used in the evaluation of the economic impact of other health-care interventions. Diagnostic tests for EGFR mutations (the gene that resource allocation decisions within their own jurisdiction.
Different types of economic evaluation exist [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] (TABLE 2) . However, in terms of application in practice, two types of economic evaluation are broadly used to quantify the costs and consequences of a new intervention: CEA (sometimes interchanged with the term cost-utility analysis (CUA)) and CBA. If economic evaluation is used to make 'ought' statements about what decision-makers should do, it must have some underlying value judgements or normative ('what ought to be') principles [40] [41] [42] . The normative underpinnings of CEA and CBA are extra-welfarism and welfarism, respectively 43, 44 . To date, the practical application of extra-welfarism, such as in the context of NICE appraisal programmes, supports the premise that decision-makers want to maximize health, which is measured using quality-adjusted life-years (QALYs). Therefore, globally, CEAs have become the type of economic evaluation recommended most frequently in guidelines to inform resource allocation and/or reimbursement decisions 45 .
encodes the epidermal growth factor receptor tyrosine kinase) in tumours of adults with untreated non-small-cell lung cancer (NSCLC) or medicines such as erlotinib -used to treat patients with locally advanced or metastatic NSCLC confirmed to be positive for EGFR mutations -are assessed within the diagnostic assessment programme and the technology appraisal programme, respectively, as part of national decision-making frameworks employed by NICE (FIG. 1) . NICE advocates consideration of the opportunity cost for the health-care budget and the use of appropriate methods of economic evaluation to quantify the impact of a new intervention on health-care costs and population outcomes 28, 29 . In this context, two key tenets must be remembered when using economic evaluation. First, the results should inform resource allocation decisions at the population level rather than individual clinician-patient decisions. Second, the results should be used as a source of information towards evidence-based practice and cannot be seen as a substitute for careful interpretation and appraisal by regional and local decision-makers charged with making Nature Reviews | Genetics Trial-based versus model-based CEA Two approaches to produce the data to conduct a CEA exist: trial-based, whereby data for decision-making are typically and almost exclusively collected from within a single randomized controlled trial (RCT), or model-based, whereby data are collected from multiple diverse sources and synthesized within an economic model.
Local
CEA poses a specific practical challenge in the context of genomic diagnostic tests. A genomic test must be embedded within a service delivery model, which is likely to preclude the practical implementation of a randomization process necessary for an RCT comparing diagnostic tests using next-generation sequencing technologies with current diagnostic strategies. This approach is further complicated by
Trial-based CEA. The timeliness for generating evidence from trial-based studies that collect cost and consequences data at the individual patient level can limit their use for decision-making in practice 46 . Trial-based studies are also resource intensive, are relevant only to the trial protocol and have challenges when generalizing to other jurisdictions or patient populations 47 . Using a trial-based
Glossary

Budget impact
The total budget impact of a new technology in terms of the cost falling on the budget holder. Budget impact should be calculated by considering the perspective of the specific health-care decision-maker, the size and characteristics of the population, the current and new treatment mix, the effectiveness and safety of the new and current treatments, the resource use and costs for the treatments and symptoms as they would apply to the population of interest.
Companion diagnostics
Also referred to as the test in a test-and-treat strategy. Diagnostic tests (typically an in vitro diagnostic) co-developed alongside a pharmaceutical agent and stated explicitly within the product label as it is essential for the safe and effective use of the corresponding medicine.
Cost-benefit analysis (CBA). A type of economic evaluation that compares the relative costs and consequences of different courses of action in which the consequences are measured using an approach that captures the impact in terms of money, such as willingness to pay.
Cost-consequences analysis
(CCA). A type of economic evaluation that compares the relative costs and consequences of different courses of action in which the consequences are measured using different outcomes and presented separately.
Cost-effectiveness analysis
(CEA). A type of economic evaluation that compares the relative costs and consequences of different courses of action, in which the consequences are measured using outcomes that capture the impact on clinical effectiveness. Often used synonymously with cost-utility analysis, in which the consequences are measured using quality-adjusted life-years.
Cost-effectiveness threshold
The additional cost that must be imposed on the budget for health care to displace one quality-adjusted life-year (QALY) elsewhere within the health-care system. Interventions that increase cost but with an incremental cost per QALY below the threshold are typically viewed as being cost-effective. NICE (National Institute for Health Care Excellence) uses a threshold range thought to be between £20,000 and £30,000 per QALY gained.
Cost-minimization analysis
(CMA). A type of economic evaluation that compares only the relative costs of different courses of action as it is assumed that the consequences are equal.
Decision analytic model
A series of mathematical relationships that represent the progression of a patient's diagnosis or disease and the impact of a health technology on diagnosis and/or disease progression. The output of a decision analytic model can be expressed in terms of the expected outcomes of interest for each alternative comparator strategy.
Decision problem
An explicit statement of the resource allocation decision under consideration.
Decision trees
A decision analytic modelling technique that simulates a cohort of patients following a predefined pathway with associated probabilities, costs and outcomes. Decision trees do not typically incorporate a time component.
Discrete event simulation
(DES). A decision analytic modelling technique that simulates the histories of individual patients over time, characterized by the specific events that they may experience.
Extra-welfarism
A set of normative principles that guides the conduct, design and interpretation of an economic evaluation. Extra-welfarism is typically taken to underpin the use of cost-effectiveness analysis as the method of economic evaluation and the quality-adjusted life-year as the metric of benefit and/or outcome.
Incremental costs
The difference in cost between two alternative interventions.
Incremental net benefit
(INB). Can be measured in monetary units (incremental net monetary benefit) or units of health gain (incremental net health benefit). If measured in monetary units (for example, dollars or euros), the monetary difference between expected net benefit of the new intervention and the expected net benefit of the relevant comparator.
National Institute for Health and Care Excellence
(NICE). The decision-making authority responsible for making recommendations regarding the allocation of population health-care resources in England.
Opportunity cost
The benefit forgone from the next best use of a specific resource. The opportunity cost of resource allocation decisions for health care can be expressed in the health benefits forgone.
Probabilistic sensitivity analysis
A form of sensitivity analysis where uncertainty is propagated through the characterization of input parameters as probability distributions and the sampling of values for parameters using Monte Carlo simulation
Quality-adjusted life-years (QALYs). A generic outcome measure of health benefit calculated by multiplying each year of life by a weight that represents its health-related quality of life. Weights are calculated according to the reference points of one (full health) and zero (death); states worse than death are possible.
Reference case
A prespecified preferred set of criteria for conducting an economic evaluation. A reference case is typically an expression of a decision-maker's value judgement.
State transition Markov models
A type of decision analytic model that conceptualizes a problem by defining relevant health states through which a cohort of patients transitions over time.
Study perspective
The scope of the costs that should be included in an economic evaluation. The perspective is typically defined by the budget constraint of the decision-maker. Examples include a health-care system perspective and a societal perspective. The perspective also helps to determine the relevant outcome chosen for analysis.
Time horizon
The scope of the costs and consequences that should be included in an economic evaluation, from the present until a defined point in the future. The time horizon for a study should be sufficient to allow all relevant costs and consequences to be incorporated, which, in general, requires a lifetime time horizon to be used. The lifetime is taken to be that of the last dying patient within the analysis cohort.
Uncertainty
A key component of any economic evaluation. There are different types of uncertainty, such as parameter, methodological and decision. The impact of parameter and methodological uncertainty can be captured using sensitivity analysis, such as probabilistic sensitivity analysis or scenario analysis, respectively. Decision uncertainty is the probability that an incorrect decision is made in the context of resource allocation decisions for health care.
Welfarism
A set of normative principles that guides the conduct, design and interpretation of an economic evaluation. Welfarism places individual utilities at the heart of the evaluative space and is typically taken to be consistent with the use of cost-benefit analysis and the use of willingness to pay as the metric of benefit and/or outcome.
the prohibitively large research budget needed to follow up patient outcomes and resource use over a sufficient time horizon to produce relevant evidence for decision-makers.
the analysis using methods such as network meta-analysis 47 . Results can be extrapolated to capture the impact of an intervention over the lifetime of a cohort of patients and can also quantify the impact of uncertainty [48] [49] [50] .
Model-based CEA. Using a model-based CEA allows all interventions and relevant comparators (comparators are defined as relevant by the stated decision problem), such as current clinical practice, to be included in ICER, incremental cost-effectiveness ratio; LYG, life-years gained; NICE, National Institute for Health and Care Excellence; QALYs, quality-adjusted life-years.
a Same general approach to quantify the costs of each relevant technology by identifying the relevant types of resources. Relevance in this context is defined by the chosen study perspective and time horizon and by using unit costs for each resource to calculate the total cost. b CEA is, in some situations, such as within the NICE programmes, used instead of the perhaps more accurate term CUA, which is what NICE is actually advocating as it suggests QALYs. This paper adopts this approach. Uncertainty in a model-based study can arise for a number of reasons: a methodological uncertainty of how to value costs and benefits that will occur in the future using the appropriate discount rate; a structural uncertainty about which diagnostic and treatment pathways should be represented in the model structure; or a parameter uncertainty about the true value of each input parameter used within the model 50 . Sensitivity analysis is, therefore, a key component of any model-based economic evaluation. Methods that are used to measure the impact of parameter uncertainty, such as probabilistic sensitivity analysis, are viewed as prerequisites to a robust analysis 51, 52 . Combined, the ability to represent many comparators, the inclusion of the impact of uncertainty and the extrapolation to a long time horizon have all contributed to decision analytic model-based CEA globally becoming the preferred approach to quantify the incremental costs and consequences of a new intervention 27, 28, 53, 54 .
A key challenge for model-based CEA for genetic and genomic tests, and more broadly for any diagnostic test, is whether evidence exists that spans the three component parts of the intervention simultaneously: the technology; the diagnostic component; and the intervention within the health-care service delivery framework 21 . NICE describes such evidence as being 'end to end' , that is, starting from performing the original test all the way to patient outcomes and costs 29 . The only known example of a published end-to-end study in the context of genetic testing used a pragmatic trial design 55 with integrated CEA 56 to assess the use of genotyping tests for single-gene mutations (versus no genotyping) when treating patients with azathioprine; this study highlighted the problem of simply assuming that genetic information will mean that clinicians appropriately modify their treatment decisions. Where such studies are not available, assumptions must be made as to how the component parts of the diagnostic technology interact, such as how different diagnosis patterns from the new technology lead to changes in treatment choices (and subsequent benefits and costs) when the set of studies are connected within an economic model.
Model-based CEA of genomic tests
The key steps in a model-based CEA of a genetic or genomic test broadly mirror those for diagnostic tests 25, 48, [57] [58] [59] [60] [61] [62] [63] (FIG. 2) .
To ensure that the resulting model-based CEA is relevant for decision-making, the fundamental step is to explicitly define inform the cost-effective use of a national budget for health care 28, 29 . However, guidelines used by some jurisdictions, for example, the Netherlands, suggest broadening the viewpoint to use a societal perspective, which would include patient costs in addition to health-care costs 45 . The decision to use the societal perspective in the Netherlands is based on a value judgement that costs outside the health-care sector ought to be considered.
The time horizon for a study should be sufficient to allow all relevant costs and consequences to be incorporated, which, in general, requires the lifetime time horizon for the defined patient cohort to be used 23 . For example, a lifetime horizon would capture the lifelong costs and consequences of using a test to target the use of a medicine to treat cancer. the decision problem underpinned by appropriate normative principles. That is, the following aspects must be defined: the study perspective, the time horizon, the relevant study population, the intervention to be evaluated and its relevant comparators.
The study perspective should be informed by the end user of the results of the CEA. If the decision-maker (FIG. 1) is based within a hospital, then the relevant perspective will be defined by the hospital budget. By contrast, a national-level decision-maker would need a study perspective that includes all health-care resource use, consistent with the need for information on how to spend the national health-care budget. The study perspective is most often constrained to the health-care system because CEA is generally used to Nature Reviews | Genetics Define the decision problem 25 Present results
25,48,63
• Define the study perspective and time horizon • Define the intervention • Define the relevant study population
• Identify the relevant comparators • Describe the relevant diagnostic or treatment pathways using expert opinion Importantly, defining the decision problem also involves having a clear understanding of the relevant patient population that will accrue the benefits (and harms) of the intervention. However, defining the relevant population can be problematic for genomic tests. For example, when considering the added value of whole-genome sequencing, the relevant patient population may extend beyond the index patient first tested and include family members. In this instance, the decision problem could be specified to take account of externalities that capture the additional impact of genomic testing on the family (sometimes referred to as spillover effects) 64 . Including spillover effects introduces another problem that compounds how to conceptually define a lifetime as it is no longer readily apparent which lifetime for which patient or patients is appropriate, as the potential value of the intervention may span generations 13 . Defining the decision problem requires an explicit statement of the intervention and the relevant comparators, which may include strategies beyond the test itself. For example, companion diagnostics (used in test-and-treat strategies) may be compared with other medicines that are prescribed without a test. Different tests may also be considered as relevant comparators. For example, a range of technologies can be used to assess EGFR mutations for patients with NSCLC who are treated with different targeted medicines (such as the tyrosine kinase inhibitors gefitinib or erlotinib), depending on the identified mutation 65 . Numerous diagnostic applications of genetic and genomic tests also exist, as listed in the UK Genetic Testing Network database (https://ukgtn.nhs.uk/ find-a-test/), and are emerging for disorders for which there are currently no available treatments, as is often the case with rare inherited conditions. In these cases, and specifically for a genome-based diagnostic test, where incidental findings are possible 18 , there is a need to be explicit when defining the intervention under evaluation about how (and whether) such findings will be reported to the clinician ordering the test and the affected patient. Furthermore, the approach used to interpret incidental findings needs to be known and described. Multidisciplinary committees comprising groups of specialist geneticists, counsellors and molecular scientists are becoming common practice as an approach to decide on the reported test result in some, but not all, clinical settings where next-generation sequencing technologies have been used to produce a diagnostic test 18 . suggested treatment or preventive strategy in the CEA 29 . BOX 1 shows an example of when a model-based CEA was used to assess the added value of different tests that were being used in test-and-treat strategies in clinical practice. The challenges associated with conducting CEA of diagnostic tests in test-and-treat strategies have been well described 66 and include a need for clarity about whether the diagnostic test is designed to detect somatic or germline mutations and the careful framing of the study question and relevant clinical pathways while also taking into account the general lack of key data requirements for an economic evaluation of the clinical effectiveness, clinical utility, impact on health status and resource use and uptake of the test in practice 64 . By contrast, model-based CEA has not yet become routine to inform the introduction of genetic or genomic tests for disorders with no available treatments, such as rare inherited disorders that affect fewer than 1 in 2,000 individuals. This is likely to be the result of
Challenges of CEAs for genomic tests
The challenges of conducting model-based CEA for genetic or genomic tests can be grouped into (1) whether a known treatment is available, as in the case of a companion diagnostic (linked test-and-treat strategies) or where subsequent preventive strategies may be offered (for example, in the case of inherited cancers), and (2) whether no treatment options are currently known, as in the case of diagnostic tests for some rare inherited conditions (for example, hereditary ataxias, a group of rare neurodegenerative diseases) 12 . Current economic evaluations of companion diagnostic tests tend to focus on the value of the treatment or preventive strategy rather than on quantifying the value of the diagnostic test per se 66 . Some evaluation programmes have been developed specifically to assess the added value of diagnostic tests; however, these currently still focus on quantifying the value of the There was insufficient evidence for the committee to make recommendations on the following five methods:
• High-resolution melt analysis • Pyrosequencing combined with fragment length analysis • Single-strand conformation polymorphism analysis • Next-generation sequencing • therascreen EGFR Pyro Kit (CE marked, Qiagen)
Box 1 | Example of using model-based CEA to inform clinical practice
Model-based cost-effectiveness analysis (CEA) has been successfully used to assess the added value of ten different companion diagnostic tests being used in clinical practice. Specifically, the decision problem was defined as follows: what is the relative effectiveness and cost-effectiveness of epidermal growth factor receptor tyrosine kinase (EGFR) mutation testing in patients with locally advanced or metastatic non-small-cell lung cancer?
the many notable challenges associated with using model-based CEA in this context 13, 18, [67] [68] [69] [70] . Although economic evaluations of genetic and genomic tests for rare diseases have been published (see Supplementary information S1), model-based CEA has yet to be used to inform the introduction of these diagnostic tests into clinical practice. A summary of the notable challenges when conceptualizing, designing and using the results of model-based CEA for genomic tests, specifically when no treatment options are available, is now described and categorized according to four types of challenge: methodological, technical, practical and organizational (TABLE 3) .
Methodological challenges. Relevant methods must be selected to address the defined decision problem while remaining consistent with the agreed normative framework. TABLE 3 outlines several key methodological challenges, three of which are described here in detail. A review conducted in 2015 explored the impact of using CBA (underpinned by welfarism) or CEA (underpinned by extra-welfarism) on technology adoption decisions 71 . This study found that the two methods often lead to different recommendations on which health-care technology to adopt. The authors conclude that health economists do not currently provide the users of economic evaluations with sufficient guidance about which method (CBA or CEA) should be preferred, which should be the focus of future work.
Some commentators have suggested extending economic evaluations beyond health status to include 'personal utility' to value the benefits of genetic or genomic tests. Personal utility refers to the potential value resulting from the genomic information derived from a test in its own right (positive or negative) regardless of whether treatment decisions and the health of the population are affected by the test result [72] [73] [74] [75] . To date, however, no measure exists for personal utility to be used in an economic evaluation. One published study took an empirical approach to understand whether health status alone was sufficient to capture the consequences of genetic tests and services 76 . The study suggested that the consequences can be captured using a concept related to the capability to make an informed decision (in the study referred to as 'empowerment'). This conclusion should also be applicable to the evaluation of genomic tests. However, the study did not produce an instrument that could measure the capability to make use a cohort-based approach, sometimes combined with decision trees 84, 85 . In theory, these types of models can cope with any number of relevant comparators, but in practice, they are generally limited to comparing two or three interventions. One published example, a CEA of stratified breast screening programmes 86 , used optimization methods to inform how to reduce the number of comparators by selecting only the optimal programmes for inclusion in the analysis. An optimal programme was defined by solving the knapsack problem 87 . The knapsack problem defines the decision problem in terms of how to 'pack' a set of items (individual screens in the breast screening programme) of defined value (total number of QALYs) into a knapsack (the screening programme) that can hold a fixed total amount (total screens in a lifetime) in such a way that the value of the 'packed' items is maximized. Optimization methods have advantages over current methods that consider a large number of scenario analyses within a CEA to represent the many potential alternative screening programmes 88, 89 . The inherent characteristics of cohort state transition Markov models mean they may not be sufficient to capture the impact of comparing multiple interventions together with the extensive individual patient variation in terms of underlying genotype and presenting phenotype 58 . For example, the comparison of a new genomic test, such as a multiple (105) gene panel test 90 for the diagnosis of inherent retinal dystrophies, with many potential existing diagnostic strategies that use Sanger sequencing of individual genes and existing non-genetic diagnostic strategies would require a model to include many potential comparisons and account for individual patient variation 91 . More relevant but potentially complex models, such as discrete event simulation (DES), can be used to reflect the multitude of care pathways, heterogeneity in patient-level characteristics and time-related (temporal) health events that occur in the progression of disease or the diagnosis and treatment pathway 60, 91, 92 . Such models allow the health experiences of individual patients within the model to depend on their characteristics (such as age or gender) or other relevant individual-level factors (such as genotype or phenotype). Using DES also enables an estimate of the impact of a key stated advantage of genomic tests (offering patients the opportunity of an earlier diagnosis compared with existing strategies) and an assessment of whether the expected an informed decision. The authors suggest, appropriately, that further empirical research is required to understand the impact on opportunity cost if non-health-related consequences are to be included as an additional factor to be considered in CEA. Instruments have been developed that allow a broader interpretation of extrawelfarism, such as the suite of measures of capability called ICECAP (Icepop capability measure) 77, 78 , which captures the impact on well-being (interpreted as 'the ability to function'). NICE guidance currently recommends the ICECAP measures as an option in the economic evaluation of social care interventions 79 . However, using such measures of capability in a CEA does not currently yield meaningful ways of presenting the results to decision-makers that are equivalent to the presentation of QALY-based analyses, although work in this area is ongoing 80, 81 . Another methodological challenge being addressed is the potential need to move away from estimating average costs and benefits for a population and to take into account the relative cost-effectiveness at the subgroup or the individual patient level when calculating the relative cost-effectiveness of genomic-based interventions. Analytical approaches that calculate the value of heterogeneity (in, for example, patient or disease characteristics) or value of preference heterogeneity use new theoretical frameworks developed to assess the potential value of identifying cost-effective treatments for defined subgroups of patients or for individual patients given their preferences, respectively. These approaches can therefore in theory compare the value of individualized treatment decisions with the value of treatment decisions based on traditional population-level CEA, but, to date, there are no published examples in the area of genomic tests 82, 83 .
Technical challenges. Technical challenges refer to the need to account for the complexity of the decision problem in the model-based CEA in terms of the characteristics of the relevant study population, the number of relevant comparators and the potential diagnostic and, if appropriate, subsequent treatment pathways. Extensive model conceptualization techniques may be valuable to ensure that the structure of a de novo decision analytic model is relevant to the prevailing decision problem 57 (FIG. 2) . The most commonly used models in published CEAs are state transition Markov models, which positive impact is realized 21 (personal communication, N. Davison, The University of Manchester). However, the use of DES in this context remains unpublished 92 . The majority of current applications of model-based CEA assume that all processes of providing care and associated items of resource use are available with no limits, regardless of the volume of the intervention required 58 . This means that effectively, there are no constraints on the capacity of the system to provide health-care services. The assumption of infinite capacity may not be the case for a variety of reasons; there are many potential types of constraints that are internal to a health-care system, such as lack of equipment, data storage or health-care workforce. Such capacity constraints consider the impact of capacity constraints when introducing a genetic or genomic diagnostic test into practice.
Practical challenges. Even if the methodological and technical challenges have been addressed, practical challenges regarding research design may arise. A practical challenge associated with the use of model-based CEA is the lack of the required robust data to populate the model input parameters for outcomes, probabilities and resource use, in general, and end-to-end evidence, specifically. End-to-end evidence refers to evidence that captures all elements of a test-and-treat strategy by following a patient from their observed test result to a specific treatment decision and then to will affect the ability of a health-care system to reach its stated goal, such as the provision of health care to realize patient benefits. In reality, all systems, including health-care systems, resemble networks of chains, in which each event is dependent on the preceding event 93 . The discipline of mathematical optimization offers programming techniques to select the best combination of inputs from a set of available alternatives to maximize output (for example, health gain) while taking into account capacity constraints 94, 95 . There is emerging interest in the combined use of decision analytic modelling with mathematical optimization techniques to consider whether, and how, model-based CEA of health-care interventions can A further practical challenge that compounds the lack of accurate resource use data is the absence of a transparent national pricing tariff for genomic tests 24 . One systematic review indicated the impact of this challenge when it aimed to identify economic evaluations of genomic sequencing technologies but found only five studies purportedly conducting cost analyses of sequencing technologies with insufficiently reported detail on the actual methods used to identify resource use and attach unit costs 97 . There are emerging examples of using microcosting methods to understand the cost of tests, such as the approach taken to identify the cost of an antidrug antibody and drug-level test to target the use of adalimumab for people with rheumatoid arthritis 98 . The lack of a nationally agreed unit cost effectively means that an analyst is trying to perform a CEA of an intervention for which the acquisition cost is not known. In practice, the analysis can still be done using an estimated unit cost for the test, but the results of a CEA may then not be useful to decision-makers, who will not know whether the results apply in their setting.
Organizational challenges. Although mentioned last, organizational challenges present the most substantial hurdle for decision-makers who want to use the results of model-based CEA of genomic tests to inform treatment strategies or for diagnosing rare inherited diseases. Organizational challenges refer to the apparent disconnect between the organization of health-care systems and funding streams. These differences mean that a decision-maker must understand whether and how the results of a model-based CEA are relevant to their own setting based on the scope of the analysis as defined by the decision problem.
Both within and across countries, health-care systems have different service provision and staffing models for different sectors (community, general practice, Realizing the benefits of genomic tests? There is substantial but disparate evidence to support the economic impact of genetic tests and precision medicine more broadly, but limited examples exist in the area of genomics. Precision medicine includes approaches that use genetics but also other influential factors, such as the environment and patient characteristics, to identify the most suitable treatment or preventive strategy for an individual 101 . Some 45 systematic reviews have assimilated economic evaluations in the general area of precision medicine and related areas, covering test-and-treat strategies (of which some used nongenomic strategies) and genomic tests used for diagnosis, generally for single-gene disorders (see Supplementary information S1). Until 2016, there were no published economic evaluations of new sequencing technologies, although examples of CEA, some using diagnostic yield as the measure of effectiveness and some using QALYs, are now emerging that evaluate the use of next-generation sequencing in the context of gene panels for exome sequencing and three hypothetical applications (cardiomyopathy, colorectal cancer and in healthy individuals) of returning incidental findings 23, [102] [103] [104] [105] [106] [107] . This collective evidence base shows that the greatest focus is directed towards evaluations in developed countries and that it is difficult to reach a collective definitive view on whether health-care systems can realize the potential benefits from genomic tests. Collating this literature illustrates a substantial challenge for decision-analysts and decision-makers who want to have an overall view of the supporting evidence base on the economics of genomic tests: inconsistency in terminology. There is no agreed or standardized use of terms within published papers or electronic databases relevant to genomic-targeted diagnostic tests, such as precision medicine, stratified medicine, personalized medicine, individualized medicine, targeted medicine, pharmacogenetics or pharmacogenomics 108 . The early stages of any HTA or the conceptualization and development (FIG. 2) of a decision analytic model involve collating all available economic evidence, in the form of published economic evaluations, to understand the current knowledge base on a topic and to identify whether any existing decision analytic models can be used as the basis for a proposed economic evaluation 28, 29 . Examination of the disparate nature of the results from 45 systematic hospital and specialist) and a means of allocating funding to these different sectors. The existence of silo budgets, inextricably linked to the silo approach to the management of disease, creates another specific challenge when using the results of CEAs. Methods of economic evaluation assume that money can be freely moved around a health-care system so that patient benefits can be maximized by funding the most efficient service as identified by the results of the analysis. In practice, this is not the case, and this organizational issue is particularly relevant for specialized services, such as genomic medicine for people with complex diseases, who require access to many types of services across the health-care system. The cost of a genomic-targeted diagnostic test may, for example, fall to the clinician ordering the test from cardiology, as problems with the patient's heart were the presenting symptom, even if it emerges that the patient has a syndromic condition.
The results of a model-based CEA may show that achieving a diagnosis can realize benefits across disparate and unconnected areas of the health-care service. However, a decision-maker may be in charge of one distinct budget, such as for cardiology, and may not appreciate other benefits that are accrued.
On a global scale, genomics and the associated health technology assessment (HTA) are the dominion of the prosperous and, perhaps unsurprisingly, are focused within high-income countries with relatively large health-care budgets and formalized models of service delivery. Some approaches have attempted to overcome global disparities in HTA. For example, NICE International provides practical support and advice to governments and funding agencies about the process and methods of HTA in health-care policy decisions. The premise was that most countries could not afford to set up a system equivalent to NICE owing to a lack of funds and expertise. In 2013, the Bill and Melinda Gates Foundation funded a collaboration led by NICE International to develop the Gates reference case, which outlined 11 principles to ensure that economic evaluations provide robust evidence for global health-care decisionmaking 99, 100 . NICE International has now been replaced by the Global Health and Development Group (https://www.imperial. ac.uk/global-health-innovation/) to continue to provide advice to contribute to the effective, equitable use of resources and better global health.
reviews (see Supplementary information S1) reveals that it is virtually impossible to identify all the relevant evidence from one review given the inconsistency in nomenclature. If proponents of the use of genomic diagnostic tests want to realize their benefits in practice, an important first step will be to agree upon a set of consistent terms and definitions. However, reaching agreement about the appropriate terms and definitions across the broad community of stakeholders, which includes clinicians, patients, industrial partners who manufacture medicines and tests, and national assessment agencies, will require a concerted effort by internationally recognized experts using appropriate consensus methods.
Conclusions
Driven by the development of new sequencing technologies and national research agendas, there will be an increase in the number of available genomic tests in the developed world. Evaluation frameworks for genetic tests exist, but it is reasonable to suggest that these are not sufficient given the potential new demand for genomics within existing models of service delivery and beyond into mainstream medicine. Given the finite nature of health-care budgets, decision-makers need to understand the opportunity cost of introducing new genomic diagnostic tests. Model-based CEA is a useful tool embedded within HTA programmes to provide explicit information on the incremental costs and consequences of new interventions. To inform decisions about efficient allocation of health-care resources, model-based CEAs must be supported and populated by robust studies, which ideally span the three component parts of a genomic test: (1) the technology; (2) the diagnostic component; and (3) the model of service delivery to provide the diagnostic test and, if appropriate, subsequent treatment options. The area of genetics has an emerging economic evidence base. National research agencies have appropriately started funding the development of new technologies to inform new genomic tests that may replace existing genetic tests. It is now time to direct funding to support the empirical research needed to develop the use of decision analytic model-based CEAs of genomic tests while being cognizant of the known methodological, technical, practical and organizational challenges to maximize the potential benefits to patient populations.
